Introduction
decrease the occurence of post-transplant lymphoproliferative disorders. Kuo et al. (1995) observed failure of currently used regimens of acyclovir and ganciclovir as prophylactic therapy against primary EBV infection, EBV reactivation and subsequent development of post-transplant lymphoproliferative disorders.
The aim of the present study was to investigate the potency and selectivity of different classes of compounds against EBV as monitored by inhibition of EBV DNA replication and virus capsid antigen (VCA) expression. Because of their known anti-EBV efficacy, acyclovir (Colby et al., 1980) , ganciclovir (Cheng et al., 1983; Lin et al., 1984) , cidofovir (HPMPC) (Lin et al., 1991) and the antiretroviral drug zidovudine (AZT) (Lin et al., 1988) were included as reference compounds.
Materials and Methods

Inhibition of viral DNA synthesis
The EBV producer cell line P3HR-1, the EBV genomecarrying B cell lines Raji and Namalwa, as well as the EBV-negative B cell line Ramos were grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 1% L-glutamine and 1.5% sodium bicarbonate.
Exponentially growing P3HR-1 cells were centrifuged, resuspended in fresh medium and seeded at a density of 10 6 cells/ml in 25 cm 2 cell culture flasks. The tumour promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA; Sigma) was added at a concentration of 30 ng/ml to induce virus production (Lin et al., 1979) . Cell cultures were incubated with the compounds at different concentrations for 7 days. Cells were harvested and washed once with PBS. DNA was extracted using a DNA extraction kit (QIAamp Blood Kit; Qiagen).
Ten µg of total cellular DNA of drug-treated P3HR-1 cells and control cells were spotted onto a nylon membrane (Hybond-N; Amersham). Blotting was done using a vacuum-connected slot-blot apparatus. After treatment of the membrane for 5 min in denaturation solution (1.5 M NaCl, 0.5 M NaOH) and 1 min in neutralization solution (0.5 M Tris-HCl pH 7.5, 3 M NaCl), target DNA was fixed onto the membrane by UV-crosslinking. For prehybridization, the filter was incubated for 1-3 h at 42ºC in 5×SSC, 5% blocking reagent (Boehringer Mannheim), 0.1% N-laurylsarcosin, 0.02% SDS and 50% formamide. Hybridization was carried out for 12-18 h at 42ºC using 30 ng/ml of a digoxigenin-11-dUTP-labelled probe specific for the BamHI W fragment of EBV. The membrane was washed at high stringency (2×SSC and 0.1% SDS) for 10 min at room temperature followed by 2×15 min in 0.1×SSC, 0.1% SDS at 65ºC. Chemiluminescence detection was carried out as follows. After 2×15 min incubation in blocking buffer (0.2% blocking reagent, 1×PBS, 0.1% Tween 20) the filter was incubated with an anti-digoxigenin antibody conjugated with alkaline phosphatase (Anti-digoxigenin-AP, Fab fragments; Boehringer Mannheim; diluted 1 : 5000 in buffer consisting of 0.2% blocking reagent, 1×PBS) for 30 min. This was followed by 2×15 min washing in 1×PBS and 0.3% Tween 20. After 5 min preincubation in the assay buffer (0.1 M diethanolamine, 1 mM MgCl 2 ) chemiluminescent substrate solution (0.25 mM CSPD, Tropix), in assay buffer was added for 5 min. All steps were carried out at room temperature. The membrane was exposed to a Kodak film for about 4 h. Blots were scanned densitometrically and the 50% inhibitory concentration determined.
For confirmation of results obtained by slot-blot analysis, samples were analysed by Southern blot hybridization. Ten µg of extracted P3HR-1 DNA were digested with BamHI for 3-5 h at 37ºC and were separated by electrophoresis on a 0.8% agarose gel. DNA was denatured (1.5 M NaCl, 0.5 M NaOH, 20 min), neutralized (0.5 M Tris-HCl pH 7.5, 3 M NaCl, 20 min) and transferred to a nylon filter membrane by capillary blotting in 10×SSC overnight. After fixation of the target DNA onto the membrane by UV-crosslinking, the filter was processed as described above.
Preparation of the probe for hybridization
The probe was labelled in a PCR reaction according to the method described by Emanuel (1991) . The primer sequences 5′-3′ CCAGAGGTAAGTGGACTT and GACCGGTGCCTTCTTAGG delimit a 124 bp sequence within EBV internal repeat 1 (BamHI W region). The PCR reaction mixture consisted of PCR buffer (50 mM KCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl at pH 8.3, 0.01% gelatin), 200 µM each of the nucleotide triphosphates dATP, dCTP, dGTP and dig-dUTP/dTTP (relation 1 : 2), 1 µM of each primer, 2.5 units Amplitaq DNA polymerase and 50 ng (per 50 µl reaction mixture) of EBV BamHI W plasmid DNA. After an initial denaturation step for 5 min at 94ºC, 30 cycles were carried out, each including 1 min at 95ºC for denaturation, 1 min at 60ºC for annealing and 1.5 min at 72ºC for chain elongation, followed by an additional 7 min at 72ºC in a DNA thermal cycler.
Determination of cytostatic potential of compounds on P3HR-1 cell growth P3HR-1 cells were grown for 7 days in the presence or absence of the test compounds at different concentrations from an initial density of 2×10 5 cells/ml in 96-well plates. Cell numbers were measured with a Coulter counter and 50% cytostatic concentration (CC 50 ) values were calculated after subtracting the input cell number.
Inhibition of EBV antigen expression
For detection of virus capsid antigen (VCA) or early antigen p85, exponentially growing P3HR-1 cells were seeded at a density of 10 6 cells/ml with addition of TPA (30 ng/ml) and treated with different concentrations of the test compounds for 7 days. Then cells were spun down and washed with PBS. The pellets were resuspended at a concentration of 3×10 6 cells/ml. Drops of cell suspension were placed on slides, air-dried and fixed in acetone at -20ºC for 30 min. Antigens were detected by indirect immunofluorescence using human sera with high titres to VCA (1 : 2500) and negative for antibodies to EBV early 
Results
The anti-EBV activity of different classes of antiviral compounds was evaluated by means of an EBV DNA hybridization assay as well as by measuring the inhibition of the viral capsid antigen (VCA) expression using an indirect immunofluorescence assay. Confirmation of inhibitory effects as detected in the slot-blot was done by means of a Southern blot assay. Table 1 shows the 50% effective concentrations (EC 50 ) for inhibition of EBV DNA synthesis, the EC 50 for inhibition of VCA expression, the 50% cytostatic concentrations (CC 50 ), and the selectivity indices (SI) or ratio of the EC 50 for inhibition of viral DNA synthesis to the 50% cytostatic concentration. Acyclovir, ganciclovir, cidofovir and zidovudine, which were reported elsewhere (Colby et al., 1980; Cheng et al., 1983; Lin et al., 1984 Lin et al., , 1988 Lin et al., , 1991 to have anti-EBV activity in vitro, were included as reference compounds. In the present study, selectivity indices of 70, 24, 45 and 5, respectively were obtained for these compounds. The cyclic form of HPMPC (cHPMPC) proved about as potent as the parent compound HPMPC (EC 50 0.3 µg/ml).
A new series of 15 acyclic nucleoside phosphonate analogues with the acyclic side chain either being 2-phos-phonomethoxypropyl (PMP)-or 2-phosphonomethoxyethyl (PME) attached to the N7-or N9-position of the purine ring and with various substituents in the purine ring, were investigated for their anti-EBV efficacy (Fig. 1) . Four compounds in this series proved to be potent and selective inhibitors of the EBV replicative cycle and EBV structural protein production ( Table 1) . The most effective substances were 9-(2-PME)-6-dimethylaminopurine (1f), 9-(2-PME)-2-amino-6-benzhydrylaminopurine (2a), 7-(2-PME)-6-dimethylaminopurine (4a), and 9-(R)-(2-PMP)-6-(2-dimethylaminoethyl)aminopurine (3c). They yielded EC 50 values for inhibition of EBV DNA replication of 1.1, 1.3, 0.8 and 0.5 µg/ml and selectivity indices of 91, 29, 56 and 42, respectively. The other molecules in this series had weak to moderate anti-EBV efficacy.
The second class of compounds that were evaluated were the 2′,3′-dideoxythymidine analogues, for which we recently demonstrated activity against several herpesviruses and retroviruses (Federov et al., 1997) . From this series, 3′oximino-2′,3′-dideoxythymidine (12f) and 3′-acetoximino-2′,3′-dideoxythymidine (13f) (Fig. 1) , inhibited EBV DNA synthesis with EC 50 values of 1.5 and 0.5 µg/ml and a SI of 66 and >40, respectively. Another 2′,3′-dideoxythymidine analogue, 1-(2,3-dideoxy-3-N-hydroxy-amino-β-D-threopentafuranyl)-pentafuranosylthymine (10), also elicited marked activity against EBV in both assays and appeared to be quite selective, since the compound efficiently inhibited EBV replication (EC 50 4.1 µg/ml) and did not result in any cytostatic effect up to concentrations of >100 µg/ml.
The highest antiviral activity among all substances tested was noted with the novel purine nucleoside analogue 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242). This compound inhibited EBV DNA synthesis by 50% at a concentration of 0.5 ng/ml (SI 600) (Fig. 2) . Because zidovudine (Lin et al., 1988) , as well as several other antiretroviral compounds (Mar et al., 1995) , was shown to inhibit EBV replication we evaluated a selection of those compounds in the anti-EBV assays. Only ddC (2′,3′-dideoxycytidine) possessed activity. No anti-EBV activity was observed for the other antiretroviral compounds evaluated (ddI, ddA, ddDAPR, AzddU, D4A, HEPT, TSAO) or the nucleoside phosphonate analogues based on PMP and FPMP that are endowed with potent anti-human immunodeficiency virus activity [(R)PMPA; (R)PMPDAP; (S)PMPDAP; (S)FPMPA; (S)FPMPDAP]. Also, ribavirin had no influence on EBV replication, nor had dextran sulphate (data not shown), a compound that prevents binding of many enveloped viruses to the host cell.
In parallel with the EBV DNA inhibition assay, the indirect immunofluorescence antibody technique was performed to determine the inhibitory effect of the test substances on VCA expression. On average, 5.5±1.1% of the cells expressed VCA in the TPA-induced P3HR-1 cultures whereas this was 1.1±0.5% in uninduced cultures. All compounds that reduced EBV DNA synthesis also showed a clear reduction of VCA expression. The evaluation of EC 50 values for the different compounds by both methods (inhibition of EBV DNA synthesis and inhibition of VCA expression) yielded comparable results (Table 1) . To exclude the possibility that the inhibition of VCA expression was due to interference of the compounds with TPA induction, the effect of acyclovir, ganciclovir, cidofovir (at 50 µg/ml) or S2242 (at 2 µg/ml) was evaluated on the expression of an early antigen of EBV (EA-R-p85). No effect on the expression of this antigen was observed.
Discussion
An EBV DNA hybridization assay and VCA expression assay were employed to evaluate the anti-EBV activity of a large panel of potentially interesting antiviral compounds. The EBV VCA expression assay was previously reported by Colby et al. (1980) and Färber et al. (1987) in the study of the anti-EBV efficacy of acyclovir and pyrimidine nucleoside analogues. Bacon & Boyd (1995) also included an antigen expression assay based on ELISA when studying the activity of penciclovir against EBV. As demonstrated in Table 1 , both the DNA hybridization assay and the VCA assay lead to comparable results. Thus, the reduction of EBV VCA formation can be used as a first screening method after which potentially interesting compounds can be further investigated by an EBV DNA hybridization assay.
Among the different substances examined in the present study, the novel purine nucleoside analogue 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242) was found to be the most potent anti-EBV compound ever described, with an EC 50 of 0.5 ng/ml and a selectivity index of 600. S2242 is known to be a potent anti-herpesvirus agent in vitro and in vivo. The compound inhibits the replication of herpes simplex virus (HSV), human cytomegalovirus (HCMV), varicella-zoster virus (VZV), human herpesvirus 6 and 8 (HHV-6, HHV-8) and vaccinia virus (Neyts et al., 1994 (Neyts et al., , 1995 (Neyts et al., , 1998 Reymen et al., 1995) .
Guided by their activity against HSV, HCMV, and VZV , a new series of acyclic nucleoside phosphonates consisting of a 2-phosphonomethoxyalkyl side chain and N6-substituted 6-aminopurines were selected for the study of their anti-EBV activity. Among these series, four compounds elicited a marked anti-EBV activity. The most effective compounds were 9-(2-PME)-6-dimethylaminopurine (1f), 9-(2-PME)-2-amino-6benzhydrylaminopurine (2a), 7-(2-PME)-6-dimethylaminopurine (4a) and 9-(R)-(2-PMP)-6-(2-dimethylaminoethyl)aminopurine (3c) with 50% effective concentrations for inhibition of EBV DNA synthesis of 1.1, 1.3, 0.8 and 0.5 µg/ml and selectivity indices of 91, 29, 56 and 42, respectively. Of special interest was the activity of compound 4a, a molecule that, like S2242, has the acyclic side chain at the N7 rather than the N9 position of the purine ring. PMEA (adefovir; 1i) , the parent compound of these derivatives, is a broad-spectrum antiviral agent with activity against DNA viruses (including EBV) and retroviruses and is currently undergoing clinical evaluation (Balzarini et al., 1993; Lin et al., 1987; Naesens et al., 1997) . The cyclic form of cidofovir, cHPMPC (9), proved equally effective as the parent compound cidofovir.
Zidovudine was shown to elicit some anti-EBV activity (Lin et al., 1988) . Mar et al. (1995) reported on the anti-EBV activity of the antiretroviral compounds (+)-β-D-dioxalane cytosine and (-)-L-β-dioxalane-cytosine. The triphosphates of these substances inhibit the reverse transcriptase of retroviruses but apparently also inhibit the EBV DNA polymerization process. Guided by this information we included a variety of antiretroviral substances in the present study. However, only ddC had a moderate influence on EBV replication. Of a series of nucleoside phosphonate analogues based on PMP and FPMP that were found to be potent inhibitors of retroviruses (Balzarini et al., 1991 (Balzarini et al., , 1993 , none demonstrated anti-EBV activity. It thus appears that the anti-EBV activity of antiretroviral compounds is the exception rather than the rule.
Two novel 2′,3′-dideoxythymidine analogues emerged as selective inhibitors of EBV; 3′-oximino-2′,3′dideoxythymidine and 3′-acetoximino-2′,3′-dideoxythymidine reached EC 50 values of 1.5 and 0.5 µg/ml and SI of 66 and >40, respectively. A marked protective effect was also observed for 1-(2,3-dideoxy-3-N-hydroxyamino-β-Dthreo-pentafuranyl)pentafuranosyl)thymine (10) (EC 50 4.15 µg/ml; SI >24) (Tronchet et al., 1994) . We previously found that these molecules are also endowed with anti-HSV, but not anti-HCMV activity (unpublished results).
Higher selectivity indices for the reference compounds have been published than the values obtained in our study (Lin et al., 1992) . The reason for this may be due to the evaluation of the cytostatic action of the compounds after a 7 days incubation period (our study), rather than 4 days (Lin et al., 1992) . Furthermore we also evaluated the antiviral effect of the compounds after 7 days, instead of 14 days as in the Lin study.
In conclusion, we have described the potent anti-EBV activity of the N7-substituted acyclic nucleoside analogue 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine and of a selection of novel acyclic nucleoside phosphonate analogues and 2′,3′-dideoxythymidine derivatives.
